March 14, 2024

SS Innovations Successfully Completes World-First Mitral Valve Replacement with SSi Mantra Surgical Robotic Device

Surgical robotic technology company, SS Innovations International (OTC: SSII) has successfully performed the world’s first mitral valve replacement using the SSi Mantra surgical robotic system at the Narayana Hrudayalaya Institute of Cardiac Sciences in Bengaluru, India. SS Innovations Founder and Chairman, Dr. Sudhir Srivastava commented, “We are very proud of our team for pushing the… [Read More]
March 14, 2024

Adjusting Expectations: Bond Yields Climb Amid Inflation Pressures and Shifting Fed Rate Cut Outlook

Bond yields increased as investors revised their expectations for Federal Reserve rate reductions, driven by a surge in producer prices that underscored ongoing inflation challenges. Despite a mixed set of economic indicators that slightly reduced the urgency for the Federal Reserve to cut rates this year, bond prices dropped, reflecting a nuanced market sentiment toward… [Read More]
March 14, 2024

TG Therapeutics Reports on Phase 3 Studies of Drug for Relapsing MS

Commercial stage biopharmaceutical company, TG Therapeutics (Nasdaq: TGTX), has presented data from its ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. The company also… [Read More]
March 14, 2024

Psyence Group Headed for Phase 2 with Psilocybin Therapeutic for Adjustment Disorder Following Cancer Diagnosis

The therapeutic use of nature-derived psilocybin in mental health and wellbeing continues to rise in popularity. Psyence Group (CSE: PSYG) has announced this week that its associate, Psyence Biomedical Ltd (Nasdaq: PBM)has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate a Phase 2b study in Melbourne, Australia. Psyence’s study will… [Read More]
March 14, 2024

Made in America: Bright Green Corporation to Expand New Mexico Cannabis Facility

Bright Green Corporation (Nasdaq: BGXX) today announced it will undertake a $250 million construction project to expand the Company’s current research, production and extraction processing facility located in rural Grants, New Mexico. The company recently obtained regulatory approvals for the production of Schedule I and II controlled substancesfrom the DEA and the State of New… [Read More]
March 13, 2024

Kyverna and Stanford University Collaborate to Investigate Multiple Sclerosis Treatment

 Kyverna Therapeutics (Nasdaq: KYTX) will collaborate with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, Phase 1 investigator-initiated trial (IIT) in nine to 12 adult subjects with non-relapsing and progressive forms of multiple sclerosis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate… [Read More]
March 13, 2024

Marijuana-Consuming Rodents Disrupt New Orleans Police Evidence Storage: “They’re all high.”

In an unusual turn of events, rodents with a penchant for cannabis have been discovered consuming marijuana evidence in the deteriorating evidence room of the New Orleans Police Department, leading officials to raise concerns. Superintendent Anne Kirkpatrick highlighted the issue to the City Council’s Criminal Justice Committee, noting the presence of cannabis-loving rats within the… [Read More]
March 13, 2024

EU Passes Groundbreaking AI Regulation Amid Mixed Reactions

Despite opposition, the European Union has adopted the most detailed AI regulations to date, marking a significant moment for artificial intelligence governance globally. The EU Parliament’s approval of the AI Act positions the bloc as a potential leader in AI regulation, especially in the absence of similar legislation from the United States. This pivotal legislation… [Read More]
March 13, 2024

Artelo Biosciences a Finalist in J&J Dermatology Innovation Challenge

Clinical-stage pharmaceutical company, Artelo Biosciences, Inc. (Nasdaq: ARTL), has been named a finalist in Johnson & Johnson’s (NYSE: JNJ) Innovation Challenge in dermatology. The event is by invitation only and seeks novel approaches to treating atopic dermatitis from companies around the world. The company is developing ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, is… [Read More]